## Note
nid: 1517101912405
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_1::Zanki_Step_Decks::Zanki_Hematology_&_Oncology::Pathoma_WBC, #AK_Step1_v11::#FirstAid::02_Immunology::03_Immune_Responses::18_Transplant_Rejection, #AK_Step1_v11::#FirstAid::02_Immunology::03_Immune_Responses::18_Transplant_Rejection::Post_Transplant_Lymphoproliferative_Disease, #AK_Step1_v11::#OME_banner::Basic_Science::07_Immunology, #AK_Step1_v11::^Other::^EXPN::BGadd, #AK_Step1_v11::^Other::^FA_Updates::FA2018, #AK_Step1_v11::^Other::^HighYield::2-RelativelyHighYield, #AK_Step1_v11::^Systems::HemeOnc::WBC
markdown: false

### Text
<b>Post-transplant Lymphoproliferative Disease (PTLD)</b> is the
most common <u>malignancy</u> complicating {{c1::solid organ}}
transplantation*

### Extra
- *excluding nonmelanoma skin cancer / in-situ cervical cancer;
also not the most common <u>viral infection</u> (associate that
with CMV)
<div>
  - however, only accounts for a minority of secondary cancers
  following allogenic HSC transplant
</div>

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid


### Sketchy


### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href=
  "https://onlinemeded.org/spa/immunology?ref=anki"><img src=
  "_OME_AnkiFlashcards_Topic_3.png"></a>
</div>

### Additional Resources


### One by one

